About AstraZeneca (NYSE:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Industry, Sector and Symbol
Trailing P/E Ratio12.7025544894426
Forward P/E Ratio18.65
Sales & Book Value
Annual Sales$23.00 billion
Price / Sales3.90
Cash Flow$3.12 per share
Price / Cash11.36
Book Value$6.59 per share
Price / Book5.38
Net Income$3.50 billion
Return on Equity34.02%
Return on Assets8.37%
AstraZeneca (NYSE:AZN) Frequently Asked Questions
What is AstraZeneca's stock symbol?
AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?
AstraZeneca declared a None dividend on Friday, July 28th. Investors of record on Friday, August 11th will be paid a dividend of $0.44 per share on Monday, September 11th. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. View AstraZeneca's Dividend History.
When did AstraZeneca's stock split? How did AstraZeneca's stock split work?
Shares of AstraZeneca split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.
How were AstraZeneca's earnings last quarter?
AstraZeneca plc (NYSE:AZN) posted its quarterly earnings results on Thursday, November, 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.55. The firm earned $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. AstraZeneca's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.32 EPS. View AstraZeneca's Earnings History.
When will AstraZeneca make its next earnings announcement?
Where is AstraZeneca's stock going? Where will AstraZeneca's stock price be in 2018?
19 equities research analysts have issued 1 year price targets for AstraZeneca's stock. Their predictions range from $35.00 to $39.00. On average, they expect AstraZeneca's stock price to reach $37.00 in the next twelve months. View Analyst Ratings for AstraZeneca.
Are investors shorting AstraZeneca?
AstraZeneca saw a decrease in short interest during the month of December. As of December 15th, there was short interest totalling 8,687,524 shares, a decrease of 35.1% from the November 30th total of 13,393,297 shares. Based on an average daily volume of 3,174,072 shares, the short-interest ratio is presently 2.7 days.
Who are some of AstraZeneca's key competitors?
Some companies that are related to AstraZeneca include Merck & Co., Inc. (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), GlaxoSmithKline (GSK), Celgene (CELG), GlaxoSmithKline (GSK), Shire (SHPG), Beximco Pharmaceuticals (BXP), Shire (SHP), Teva Pharmaceutical Industries (TEVA), Valeant Pharmaceuticals Intl (VRX), Dr.Reddy's Laboratories (RDY), Catalent (CTLT) and Patheon (PTHN).
Who are AstraZeneca's key executives?
AstraZeneca's management team includes the folowing people:
- Pascal Soriot, Executive Director and Chief Executive Officer (Age 57)
- Marc Dunoyer, Executive Director, Chief Financial Officer (Age 64)
- Fiona Cicconi, Executive Vice-President, Human Resources
- Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
- Pam P. Cheng, Executive Vice President - Operations and Information Technology (Age 45)
- Ruud Dobber, Executive Vice President, North America
- Bahija Jallal Ph.D., Executive Vice President, MedImmune
- Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
- Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
- Leon Wang, Executive Vice President - Asia Pacific
Who owns AstraZeneca stock?
AstraZeneca's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (0.02%), Bank of Montreal Can (0.02%), Oliver Luxxe Assets LLC (0.00%), Fulton Bank N.A. (0.00%), First Bank & Trust (0.00%) and BLB&B Advisors LLC (0.00%). View Institutional Ownership Trends for AstraZeneca.
Who sold AstraZeneca stock? Who is selling AstraZeneca stock?
AstraZeneca's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, New England Research & Management Inc., Oliver Luxxe Assets LLC and Gofen & Glossberg LLC IL. View Insider Buying and Selling for AstraZeneca.
Who bought AstraZeneca stock? Who is buying AstraZeneca stock?
AstraZeneca's stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fulton Bank N.A., BLB&B Advisors LLC, Ingalls & Snyder LLC, First Bank & Trust, Private Trust Co. NA, Bremer Trust National Association and Atria Investments LLC. View Insider Buying and Selling for AstraZeneca.
How do I buy AstraZeneca stock?
Shares of AstraZeneca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AstraZeneca's stock price today?
One share of AstraZeneca stock can currently be purchased for approximately $35.44.
How big of a company is AstraZeneca?
AstraZeneca has a market capitalization of $88.81 billion and generates $23.00 billion in revenue each year. The company earns $3.50 billion in net income (profit) each year or $2.79 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.
How can I contact AstraZeneca?
AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge X0, CB2 0AA. The company can be reached via phone at 44-0-20-3749-5000 or via email at [email protected]
MarketBeat Community Rating for AstraZeneca (AZN)MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
AstraZeneca (NYSE:AZN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.58||2.56||2.54||2.50|
|Ratings Breakdown: ||1 Sell Rating(s)|
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$37.00||$36.60||$37.40||$38.46|
|Price Target Upside: ||5.50% upside||10.08% upside||8.02% upside||18.73% upside|
AstraZeneca (NYSE:AZN) Consensus Price Target History
AstraZeneca (NYSE:AZN) Analyst Ratings History
(Data available from 1/21/2016 forward)
AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart
AstraZeneca (NYSE AZN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q3||$0.57||$1.12||$6.00 billion||$6.23 billion||View||N/A|
|7/27/2017||6/30/2017||$0.41||$0.87||$5.04 billion||$5.05 billion||View||N/A|
|4/27/2017||3/31/2017||$0.38||$0.99||$5.40 billion||$5.41 billion||View||N/A|
|2/2/2017||Q416||$0.51||$1.21||$5.43 billion||$5.59 billion||View||Listen|
|11/10/2016||Q316||$0.48||$1.32||$5.95 billion||$5.70 billion||View||N/A|
|7/28/2016||Q216||$0.76||$0.83||$5.56 billion||$5.60 billion||View||Listen|
|4/29/2016||Q1||$0.60||$0.51||$5.96 billion||$6.12 billion||View||Listen|
|2/4/2016||Q415||$0.88||$0.94||$6.27 billion||$6.40 billion||View||N/A|
|11/5/2015||Q315||$0.51||$1.03||$5.90 billion||$5.85 billion||View||N/A|
|7/30/2015||Q2||$0.52||$1.21||$6.02 billion||$5.84 billion||View||Listen|
|4/24/2015||Q1||$1.07||$1.08||$5.87 billion||$6.06 billion||View||N/A|
|2/5/2015||Q314||$0.85||$0.76||$6.68 billion||$6.68 billion||View||N/A|
|11/6/2014||Q3||$1.04||$1.05||$6.44 billion||$6.54 billion||View||N/A|
|7/31/2014||Q214||$1.09||$1.30||$6.24 billion||$6.45 billion||View||N/A|
|4/29/2014||Q114||$1.23||$1.17||$6.32 billion||$6.42 billion||View||N/A|
|2/6/2014||Q413||$1.22||$1.23||$6.91 billion||$3.84 billion||View||N/A|
|10/31/2013||Q313||$1.27||$1.21||$6.45 billion||$6.25 billion||View||N/A|
|8/1/2013||Q213||$1.16||$1.20||$6.24 billion||$6.23 billion||View||N/A|
|4/25/2013||$1.36||$1.41||$6.54 billion||$6.39 billion||View||N/A|
|1/31/2013||Q412||$1.37||$1.56||$7.17 billion||$7.28 billion||View||N/A|
AstraZeneca (NYSE:AZN) Earnings Estimates
Current Year EPS Consensus Estimate: $1.9 EPS
Next Year EPS Consensus Estimate: $1.72 EPS
AstraZeneca (NYSE:AZN) Dividend Information
|Most Recent Dividend:||9/11/2017|
|Dividend Growth:||-21.20% (3 Year Average)|
|Payout Ratio:||49.10% (Trailing 12 Months of Earnings) |
72.11% (Based on This Year's Estimates)
79.65% (Based on Next Year's Estimates)
AstraZeneca (NYSE:AZN) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for AstraZeneca (NYSE AZN)
No insider trades for this company have been tracked by MarketBeat.com
AstraZeneca (NYSE AZN) News Headlines
AstraZeneca (NYSE:AZN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement
AstraZeneca (NYSE AZN) Stock Chart for Sunday, January, 21, 2018